Last reviewed · How we verify
CBD
CBD (cannabidiol) modulates endocannabinoid signaling and interacts with multiple receptors including serotonin 5-HT1A, TRPV1, and GPR55 to produce anti-inflammatory, anxiolytic, and analgesic effects.
CBD (cannabidiol) modulates endocannabinoid signaling and interacts with multiple receptors including serotonin 5-HT1A, TRPV1, and GPR55 to produce anti-inflammatory, anxiolytic, and analgesic effects. Used for Epilepsy (Dravet syndrome, Lennox-Gastaut syndrome), Chronic pain, Anxiety disorders.
At a glance
| Generic name | CBD |
|---|---|
| Also known as | Cannabidiol, No brand names as cannabidiol is not commercially available, AVCN319301a, CBD tincture, CBD cream |
| Sponsor | Stero Biotechs Ltd. |
| Drug class | Cannabinoid |
| Target | 5-HT1A, TRPV1, GPR55, CB1 (allosteric), CB2 (allosteric) |
| Modality | Small molecule |
| Therapeutic area | Neurology, Psychiatry, Pain Management, Immunology |
| Phase | FDA-approved |
Mechanism of action
CBD is a non-intoxicating cannabinoid that does not directly bind CB1 or CB2 receptors with high affinity but instead acts as an allosteric modulator and interacts with multiple receptor systems. It enhances endocannabinoid tone, modulates serotonergic and vanilloid signaling, and reduces neuroinflammation, contributing to its therapeutic effects across multiple conditions.
Approved indications
- Epilepsy (Dravet syndrome, Lennox-Gastaut syndrome)
- Chronic pain
- Anxiety disorders
- Inflammation-related conditions
Common side effects
- Fatigue
- Diarrhea
- Appetite changes
- Elevated liver enzymes
- Somnolence
Key clinical trials
- EFFECTS OF A FULL SPECTRUM CANNABIS EXTRACT WITH DIFFERENT DOSES OF CBD AND THC ON THE MODULATION OF FIBROMYALGIA: A PILOT, MULTICENTER, OPEN LABEL CLINICAL TRIAL (FRIDINHA) (PHASE1, PHASE2)
- Sublingual Cannabidiol for Anxiety (PHASE2)
- Safety and Effect on Pain and Function According to RAPID-3 of IHL-675A in Patients With Rheumatoid Arthritis (PHASE2)
- China Cognition and Aging Study
- The Diagnostic Cut-off Value of Core Biomarkers of Alzheimer's Disease
- Detection of Alzheimer's Disease (AD)-Related Seeds for AD Diagnosis
- Consumer Perceptions of Cannabidiol (CBD) Health Claims (NA)
- Evaluation of Smoked THC and CBD in Men and Women (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |